** Shares of Aldeyra Therapeutics rise 1.9% to $5.40 premarket

** Co says it has resubmitted its application for approval to the U.S. FDA for its dry eye disease drug

** Last year, the FDA declined to approve the drug reproxalap

** Up to last close, stock up 51% YTD

(Reporting by Puyaan Singh)

((Puyaan.Singh@thomsonreuters.com;))